Cargando…

Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis

INTRODUCTION: 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled corticosteroids (ICS),...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yixuan, Hu, Hao, Leung, Siu-wai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341520/
https://www.ncbi.nlm.nih.gov/pubmed/34351996
http://dx.doi.org/10.1371/journal.pone.0255545
_version_ 1783733932913590272
author Jiang, Yixuan
Hu, Hao
Leung, Siu-wai
author_facet Jiang, Yixuan
Hu, Hao
Leung, Siu-wai
author_sort Jiang, Yixuan
collection PubMed
description INTRODUCTION: 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting b2-agonists (LABA)(ICS/LAMA/LABA). Triple therapy in fixed-dose combinations (FDCs), i.e., combining ICS, LABA with LAMA and administrating by a single inhalation device, has appeared in recent years. This study aims to compare the efficacy of triple therapy in FDCs in treating patients with moderate to severe COPD. METHODS AND ANALYSES: Literature search will be conducted on PubMed, Embase and Web of science, according to pre-specified and corresponding search strategies, for relevant reports published since the inception dates of the databases. Randomised controlled trials (RCT) which compared the triple therapy in FDCs with other pharmacological therapies will be included. The Cochrane risk of bias assessment tool (RoB 2) will be used to assess the RCT quality. The outcomes will be analyzed as rate ratios and mean differences under a random-effects model in a frequentist network meta-analysis (NMA). Additional statistical analyses including subgroup analysis, sensitivity analysis, and publication bias analysis will be performed to assess the evidential heterogeneity and robustness. The strength of evidence from the NMA will be evaluated with the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) methods. ETHICS AND DISSEMINATION: No ethics approval is required as this systematic review and network meta-analysis do not collect confidential personal data and do not carry out interventions in treating patients. PROTOCOL REGISTRATION NUMBER: CRD42021240823.
format Online
Article
Text
id pubmed-8341520
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-83415202021-08-06 Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis Jiang, Yixuan Hu, Hao Leung, Siu-wai PLoS One Study Protocol INTRODUCTION: 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting b2-agonists (LABA)(ICS/LAMA/LABA). Triple therapy in fixed-dose combinations (FDCs), i.e., combining ICS, LABA with LAMA and administrating by a single inhalation device, has appeared in recent years. This study aims to compare the efficacy of triple therapy in FDCs in treating patients with moderate to severe COPD. METHODS AND ANALYSES: Literature search will be conducted on PubMed, Embase and Web of science, according to pre-specified and corresponding search strategies, for relevant reports published since the inception dates of the databases. Randomised controlled trials (RCT) which compared the triple therapy in FDCs with other pharmacological therapies will be included. The Cochrane risk of bias assessment tool (RoB 2) will be used to assess the RCT quality. The outcomes will be analyzed as rate ratios and mean differences under a random-effects model in a frequentist network meta-analysis (NMA). Additional statistical analyses including subgroup analysis, sensitivity analysis, and publication bias analysis will be performed to assess the evidential heterogeneity and robustness. The strength of evidence from the NMA will be evaluated with the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) methods. ETHICS AND DISSEMINATION: No ethics approval is required as this systematic review and network meta-analysis do not collect confidential personal data and do not carry out interventions in treating patients. PROTOCOL REGISTRATION NUMBER: CRD42021240823. Public Library of Science 2021-08-05 /pmc/articles/PMC8341520/ /pubmed/34351996 http://dx.doi.org/10.1371/journal.pone.0255545 Text en © 2021 Jiang et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Study Protocol
Jiang, Yixuan
Hu, Hao
Leung, Siu-wai
Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
title Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
title_full Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
title_fullStr Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
title_full_unstemmed Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
title_short Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
title_sort comparative efficacy of single-inhaler triple therapies for copd: a protocol for systematic review and network meta-analysis
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341520/
https://www.ncbi.nlm.nih.gov/pubmed/34351996
http://dx.doi.org/10.1371/journal.pone.0255545
work_keys_str_mv AT jiangyixuan comparativeefficacyofsingleinhalertripletherapiesforcopdaprotocolforsystematicreviewandnetworkmetaanalysis
AT huhao comparativeefficacyofsingleinhalertripletherapiesforcopdaprotocolforsystematicreviewandnetworkmetaanalysis
AT leungsiuwai comparativeefficacyofsingleinhalertripletherapiesforcopdaprotocolforsystematicreviewandnetworkmetaanalysis